CA-FOCAL-SYSTEMS
24.3.2022 13:54:08 CET | Business Wire | Press release
In order to better serve the retail industry with state of the art AI and to couple that with optimal operations and processes, Focal Systems is proud to announce the hiring of Suzy Monford, former Kroger executive, as Chief Strategy and Marketplace Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005148/en/
With more than 30 years’ experience in the grocery and restaurant industries, Monford brings a passion for innovating go-to-market strategies and employing cutting edge technologies that can transform the global food and retail sectors. She will be based in Austin, TX, heading the company’s office there.
“Since 2015 our team has worked with Suzy as a customer, advisor and friend to guide our product roadmap and strategy. Her advice has gotten us to where we are today. She is the smartest person in retail we have had the pleasure of working with. We are thrilled she has elected to join us at this pivotal moment in our company’s growth,” said Francois Chaubard, Focal Systems Founder and CEO. “Her leadership experience as a retailer who’s led e-commerce and technology innovations in the U.S., U. K., and Australia are hugely valuable to us and our customers as we grow around the world.”
“Throughout my career as an operator, marketer and customer experience innovator, I’ve been fortunate to work with best-in-class leaders, so I’m thrilled to join Francois and the Focal team at this moment in our industry’s evolution,” said Monford. “The need to reimagine and rebuild the world’s food economy has never been more vital—to the stores and communities we serve, and more broadly, to the environment.”
After a brief stint with PCC, Monford joins Focal following three years with Kroger. As Group Vice President of eCommerce, she helped create and lead go-to-market strategies for Kroger’s e-commerce partnership with Ocado into new markets across the U.S. During her tenure with Kroger, Monford also served as Group Vice President of Fresh, and President of QFC.
Monford began her supermarket career working for a decade in leadership roles for H-E-B. After H-E-B, she gained international experience with senior executive roles with both Woolworths and Coles, and returned to the U.S. to become CEO of Andronico’s in San Francisco, a company she is credited for turning around as she led its successful acquisition by Albertson’s Safeway.
About Focal Systems
Founded in 2015 in San Francisco out of Stanford’s Computer Vision Lab, Focal Systems is the industry leader in retail automation. Our mission is to automate and optimize brick and mortar retail with state-of-the-art deep learning and AI. We have pioneered the world’s first “Self-Driving Store”- OS that revolutionizes how stores are run. Focal has raised more than $40m to date and scaled solutions on three continents in hundreds of stores, with thousands of cameras deployed. Learn more at: https://focal.systems
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005148/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom